AFM13 is a bispecific antibody used in immunotherapy for targeting natural killer (NK) cells to tumor cells expressing CD30, a specific antigen associated with certain cancers. It binds to CD16a (FcgR3a) on NK cells and CD30 on tumor cells, enabling selective destruction of cancer cells through redirected NK cell activation. Investigated in clinical trials for hematologic malignancies such as Hodgkin lymphoma and non-Hodgkin lymphoma, particularly those expressing CD30. Enables an off-the-shelf adoptive cell therapy approach by engaging innate immune effectors without the need for patient-specific cell engineering. As a bispecific antibody, it does not rely on T-cells, making it suitable for patients with compromised immune systems. Shows potential for combination with other immunotherapies, such as NK cell therapy, to enhance anti-tumor responses.